欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
Saos-2人成骨肉瘤细胞(STR鉴定)
英文名:Saos-2
货号:ZQ0447
价格:¥1350.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

Saos-2人成骨肉瘤细胞(STR鉴定)

¥1350.00
+

Saos-2人成骨肉瘤细胞专用培养基

¥650.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2000
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

Saos-2人成骨肉瘤细胞

货号

ZQ0447

产品介绍

Saos-2细胞是一种来源于一名11岁白人女性原发性成骨肉瘤的骨肉瘤细胞系。该病人曾经多种药物治疗,包括RTG.methotrexate,adriamycin vincristine,cytoxan和aramycin-C。该细胞在免疫抑制小鼠中不致瘤,但在半固体培养基中形成集落。该细胞是研究骨肉瘤和骨生物学广泛认可的模型,由于它们的成骨细胞特性和产生骨样细胞外基质的能力。该细胞具有高水平的碱性磷酸酶活性和骨特异性蛋白(如骨钙素和骨桥蛋白)的表达,是研究骨形成和骨肉瘤病理生理的有效体外系统。它对于研究细胞对各种生化刺激和模拟骨环境的机械力的反应特别有价值。
Saos-2细胞也表现出非整倍体核型,缺少几条染色体,但有其他染色体的额外拷贝,这是许多癌细胞系的典型特征。它们对支原体呈阴性,并且具有强大的钙化能力,使它们适合与矿物沉积有关的测定。在癌症研究中,被广泛用于探讨肿瘤发生、转移的分子机制以及抗癌药物对骨肉瘤的作用,也被用来研究与成骨细胞分化和恶性肿瘤相关的基因表达谱。
由于Saos-2细胞具有高可移植性,因此可以进行基因操作,从而可以研究基因功能并验证治疗干预的分子靶点。这种适应性在了解骨癌的遗传和分子基础以及开发骨肉瘤的靶向治疗方面取得了重大进展。

注意事项:
Saos-2细胞生长80%即可传代,高密度生长时会有漂浮颗粒出现。

建议用户仔细核对培养基配方和培养条件,每隔2-3天换液一次,并在细胞融合之前进行传代培养,使细胞处于最优的培养条件。 

种属

性别/年龄

女/11岁

组织

疾病

骨肉瘤

细胞类型

肿瘤细胞 

形态学

上皮的

生长方式

贴壁

倍增时间

大约35~48小时 

培养基和添加剂

McCoy's 5A基础培养基(品牌:中乔新舟  货号:ZQ-1000)+15%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM0447

生物安全等级

BSL-1

STR位点信息

Amelogenin: X

CSF1PO: 10

D13S317: 12,13

D16S539: 12,13

D5S818: 12

D7S820: 8,10

THO1: 6,9

TPOX: 8

vWA: 18

培养条件

95%空气,5%二氧化碳;37℃

抗原表达/受体表达

 ***

基因表达

 ***

保藏机构

ATCC; CRL-7939 ATCC; HTB-85 DSMZ; ACC-243 ECACC; 89050205

供应限制

仅供科研使用

货号

ZQ0447

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


论文标题: Activation of CXCL6/CXCR1/2 Axis Promotes the Growth and Metastasis of Osteosarcoma Cells in vitro and in vivo

DOI: 10.3389/fphar.2019.00307
发表时间: 2019-03-28
期刊: Frontiers in Pharmacology
影响因子: 5.811
货号: ZQ0447
产品名称: SaOS-2 cell lines
原文链接: https://www.frontiersin.org/articles/10.3389/fphar.2019.00307/full


论文标题: Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo
DOI: 10.1016/j.yexcr.2017.11.020
发表时间: 2017-11-16
期刊: EXPERIMENTAL CELL RESEARCH
影响因子: 3.905
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0014482717306237


论文标题: Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p
DOI: 10.1080/21655979.2021.1965695
发表时间: 2021-08-23
期刊: Bioengineered
影响因子: 3.269
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.tandfonline.com/doi/abs/10.1080/21655979.2021.1965695


论文标题: Paeonol antagonizes oncogenesis of osteosarcoma by inhibiting the function of TLR4/MAPK/NF-κB pathway
DOI: 10.1016/j.acthis.2019.151455
发表时间: 2019-10-03
期刊: ACTA HISTOCHEMICA
影响因子: 2.479
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0065128119301345


论文标题: Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro
DOI: 10.1016/j.prp.2019.01.042
发表时间: 2019-01-30
期刊: PATHOLOGY RESEARCH AND PRACTICE
影响因子: 1.794
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.sciencedirect.com/science/article/pii/S0344033818316558


论文标题: MicroRNA‑208a‑3p promotes osteosarcoma progression via targeting PTEN
DOI: 10.3892/etm.2020.9385
发表时间: 2020-10-23
期刊: Experimental and Therapeutic Medicine
影响因子: 1.785
货号: ZQ0447
产品名称: Saos-2 cells
原文链接: https://www.spandidos-publications.com/10.3892/etm.2020.9385


论文标题: MicroRNA-506-3p initiates mesenchymal-to-epithelial transition and suppresses autophagy in osteosarcoma cells by directly targeting SPHK1
DOI: 10.1080/09168451.2019.1569496
发表时间: 2019-01-23
期刊: BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
影响因子: 1.297
货号: ZQ0447
产品名称: SaOS-2 cells

原文链接: https://www.tandfonline.com/doi/abs/10.1080/09168451.2019.1569496



PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)


PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)


PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)


PubMed=3040234
Rodan S.B., Imai Y., Thiede M.A., Wesolowski G., Thompson D., Bar-Shavit Z., Shull S., Mann K., Rodan G.A.
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties.
Cancer Res. 47:4961-4966(1987)


PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990
Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.
p53 functions as a cell cycle control protein in osteosarcomas.
Mol. Cell. Biol. 10:5772-5781(1990)


PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)


PubMed=10763916; DOI=10.1023/A:1006623001465
Jia S.-F., Worth L.L., Kleinerman E.S.
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
Clin. Exp. Metastasis 17:501-506(1999)


PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)


PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)


PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)


PubMed=15736406
Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Anticancer Res. 24:3743-3748(2004)


PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097
Hausser H.-J., Brenner R.E.
Phenotypic instability of Saos-2 cells in long-term culture.
Biochem. Biophys. Res. Commun. 333:216-222(2005)


PubMed=16888811; DOI=10.1002/jcb.21073
Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
J. Cell. Biochem. 100:339-348(2007)


PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)


PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729
Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.
Levels of p27(kip1) determine Aplidin sensitivity.
Mol. Cancer Ther. 6:1310-1316(2007)


PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003
Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M.
Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.
Cancer Genet. Cytogenet. 179:52-61(2007)


PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)


PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)


PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778
Huang G.-X., Yu L., Cooper L.J.N., Hollomon M., Huls H., Kleinerman E.S.
Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
Cancer Res. 72:271-281(2012)


PubMed=23144859; DOI=10.1371/journal.pone.0048262
Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
PLoS ONE 7:E48262-E48262(2012)


PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)



公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号